QHP Capital, an investor in healthcare companies in the middle market, agreed to acquire Applied StemCell, a biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics. Financial terms were not disclosed. “Applied StemCell is dedicated to supporting the biopharmaceutical and research sectors in the pursuit of delivering transformative regenerative medicine treatments and cell therapy products. We are delighted to have the partnership with QHP Capital. ASC’s technology and capabilities combined with QHP’s strategic network and deep industry knowledge will help us accelerate our vision to enable the future cell gene therapy market by creating iPSCs and cell products that present the highest efficacy, greatest safety, and the most accelerated and scalable manufacturing,” Ruby Chen-Tsai, Applied StemCell CEO.